MX2015006779A - Proteina slurp-1 para usarse en el tratamiento de enfermedades oculares. - Google Patents

Proteina slurp-1 para usarse en el tratamiento de enfermedades oculares.

Info

Publication number
MX2015006779A
MX2015006779A MX2015006779A MX2015006779A MX2015006779A MX 2015006779 A MX2015006779 A MX 2015006779A MX 2015006779 A MX2015006779 A MX 2015006779A MX 2015006779 A MX2015006779 A MX 2015006779A MX 2015006779 A MX2015006779 A MX 2015006779A
Authority
MX
Mexico
Prior art keywords
treatment
ocular diseases
slurp
protein
protein slurp
Prior art date
Application number
MX2015006779A
Other languages
English (en)
Spanish (es)
Inventor
Catherine Deloche
Claire Abadie
Sebastien Mouz
Julien Perino
Jean-Marc Combette
Original Assignee
Brightpulse Holding Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Brightpulse Holding Ltd filed Critical Brightpulse Holding Ltd
Publication of MX2015006779A publication Critical patent/MX2015006779A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177Receptors; Cell surface antigens; Cell surface determinants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0048Eye, e.g. artificial tears
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Cell Biology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
MX2015006779A 2012-12-07 2013-12-09 Proteina slurp-1 para usarse en el tratamiento de enfermedades oculares. MX2015006779A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP12196007.4A EP2740485B1 (en) 2012-12-07 2012-12-07 Protein slurp-1 for use in the treatment of ocular diseases
PCT/EP2013/075981 WO2014087022A1 (en) 2012-12-07 2013-12-09 Protein slurp-1 for use in the treatment of ocular diseases

Publications (1)

Publication Number Publication Date
MX2015006779A true MX2015006779A (es) 2015-10-29

Family

ID=47297008

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015006779A MX2015006779A (es) 2012-12-07 2013-12-09 Proteina slurp-1 para usarse en el tratamiento de enfermedades oculares.

Country Status (15)

Country Link
US (1) US10098925B2 (https=)
EP (1) EP2740485B1 (https=)
JP (1) JP6335188B2 (https=)
KR (1) KR20150108351A (https=)
CN (1) CN105188731B (https=)
AU (1) AU2013353957B2 (https=)
BR (1) BR112015013215A2 (https=)
CA (1) CA2891201A1 (https=)
CL (1) CL2015001520A1 (https=)
EA (1) EA201591095A1 (https=)
IL (1) IL239078A0 (https=)
MX (1) MX2015006779A (https=)
SG (2) SG11201503658XA (https=)
WO (1) WO2014087022A1 (https=)
ZA (1) ZA201503747B (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2740485B1 (en) * 2012-12-07 2018-10-31 Brightpulse Holding LTD. Protein slurp-1 for use in the treatment of ocular diseases
EP3689327B1 (fr) * 2019-01-24 2025-03-12 Organes Tissus Régénération Réparation Remplacement Composition pharmaceutique dans le traitement de lésions pulmonaires
CN114601915B (zh) * 2022-03-25 2023-04-07 四川大学华西医院 Slurp1蛋白在制备预防或治疗皮肤弹性纤维疾病的药物中的用途

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1257184B (it) 1992-12-22 1996-01-10 Applied Research Systems Preparato ad attivita' antinfiammatoria, anticoagulante e antitumorale
ES2359408T3 (es) * 2003-04-16 2011-05-23 Merck Serono Sa Uso de slurp-1 para tratar enfermedades relacionadas con la disfunción de receptores de acetilcolina.
US20100303788A1 (en) * 2009-05-29 2010-12-02 Allergan, Inc. Methods of Treating Chronic Neurogenic Inflammation Using Galanin Retargeted Endopepidases
US20130122066A1 (en) * 2010-07-30 2013-05-16 Biopham Gesellschaft Zur Biotechnologischen Entwicklung Von Pharmaka Mbh Drug delivery devices and growth factor formulations for accelerated wound healing
JP6144673B2 (ja) * 2011-06-03 2017-06-07 オフィディオン インコーポレイティド 血液脳関門を通過して輸送するための組成物及び方法
US9132193B2 (en) * 2012-11-05 2015-09-15 University of Pittsburgh—of the Commonwealth System of Higher Education Use of Slurp1 as an imunomodulatory molecule in the ocular surface
US9492431B2 (en) * 2012-11-08 2016-11-15 Yamaguchi University Therapeutic agent for keratoconjunctive disorders
EP2740485B1 (en) * 2012-12-07 2018-10-31 Brightpulse Holding LTD. Protein slurp-1 for use in the treatment of ocular diseases

Also Published As

Publication number Publication date
US10098925B2 (en) 2018-10-16
SG10201705592YA (en) 2017-08-30
SG11201503658XA (en) 2015-06-29
EP2740485A1 (en) 2014-06-11
BR112015013215A2 (pt) 2018-02-06
EP2740485B1 (en) 2018-10-31
US20150320831A1 (en) 2015-11-12
KR20150108351A (ko) 2015-09-25
JP6335188B2 (ja) 2018-05-30
CN105188731A (zh) 2015-12-23
CN105188731B (zh) 2019-02-05
CA2891201A1 (en) 2014-06-12
EA201591095A1 (ru) 2015-11-30
IL239078A0 (en) 2015-07-30
WO2014087022A1 (en) 2014-06-12
JP2016502558A (ja) 2016-01-28
ZA201503747B (en) 2016-03-30
AU2013353957A1 (en) 2015-05-28
AU2013353957B2 (en) 2018-05-17
CL2015001520A1 (es) 2016-05-20

Similar Documents

Publication Publication Date Title
PH12015500274B1 (en) Alkylpyrimidine derivatives for the treatment of viral infections and further diseases
MX2013003634A (es) Derivados policiclicos heterociclicos y metodos de uso de los mismos para el tratamiento de enfermedades virales.
MX2019000586A (es) Virus adenoasociados (aav) sflt-1 para usarse en el tratamiento de degeneración macular relacionada con la edad (amd).
NZ709260A (en) Polycyclic-carbamoylpyridone compounds and their pharmaceutical use
MX2021000715A (es) Composiciones y metodos para tratar trastornos metabolicos.
PH12014500865A1 (en) Compounds and methods for enhancing innate immune responses
MX2013004061A (es) Analogos de ciclosporina.
PH12015500713B1 (en) Acylaminopyrimidine derivatives for the treatment of viral infections and further diseases
EP4414376A3 (en) Novel depsipeptide and uses thereof
WO2012047951A3 (en) Human lung stem cells and uses thereof
MX2012000136A (es) Composiciones que comprenden finafloxacina y metodos para tratar infecciones oftalmicas, oticas, o nasales.
PH12014500967A1 (en) A medicament for treating anterior eye disease comprising rebamipide and a tear-retaining agent
MX2013007995A (es) Peptidos derivados de lactoferrina humana y su uso.
MX2013004062A (es) Analogos de ciclosporina.
MY150931A (en) Substituted oxazolidinones and their use
MY168778A (en) Oligonucleotide chelate complex-polypeptide compositions and methods
MY178169A (en) Topical ophthalmic peptide formulation
NZ700467A (en) Treatments suitable for malassezia infections
MX2015006779A (es) Proteina slurp-1 para usarse en el tratamiento de enfermedades oculares.
WO2015086738A3 (en) Hiv vaccine
HK1199201A1 (en) Antimicrobial peptides for treatment of infectious diseases
UA107155C2 (uk) Стабільна композиція для лікування герпесвірусних інфекцій
UA104484C2 (uk) Противірусна сполука множинної дії, її склад та спосіб лікування вірусних захворювань
WO2012105854A3 (en) Compositions for administration to the eye
PH12015501230A1 (en) Finafloxacin suspension compositions